

# Kathleen A Christie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6354150/publications.pdf>

Version: 2024-02-01

15  
papers

1,267  
citations

840585

11  
h-index

940416

16  
g-index

18  
all docs

18  
docs citations

18  
times ranked

1700  
citing authors

#	ARTICLE	IF	CITATIONS
1	Astrocytic interleukin-3 programs microglia and limits Alzheimer's disease. <i>Nature</i> , 2021, 595, 701-706.	13.7	157
2	NNT mediates redox-dependent pigmentation via a UVB- and MITF-independent mechanism. <i>Cell</i> , 2021, 184, 4268-4283.e20.	13.5	35
3	Making the cut with PAMless CRISPR-Cas enzymes. <i>Trends in Genetics</i> , 2021, 37, 1053-1055.	2.9	3
4	CRISPR/Cas9 gene editing demonstrates metabolic importance of GPR55 in the modulation of GIP release and pancreatic beta cell function. <i>Peptides</i> , 2020, 125, 170251.	1.2	15
5	Mutation-Independent Allele-Specific Editing by CRISPR-Cas9, a Novel Approach to Treat Autosomal Dominant Disease. <i>Molecular Therapy</i> , 2020, 28, 1846-1857.	3.7	13
6	Broad-spectrum anti-CRISPR proteins facilitate horizontal gene transfer. <i>Nature Microbiology</i> , 2020, 5, 620-629.	5.9	79
7	Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. <i>Science</i> , 2020, 368, 290-296.	6.0	714
8	Protein Analysis of the TGFBI <sup>R124H</sup> Mouse Model Gives Insight into Phenotype Development of Granular Corneal Dystrophy. <i>Proteomics - Clinical Applications</i> , 2020, 14, e1900072.	0.8	2
9	Listeria Phages Induce Cas9 Degradation to Protect Lysogenic Genomes. <i>Cell Host and Microbe</i> , 2020, 28, 31-40.e9.	5.1	54
10	Gene Editing for Corneal Stromal Regeneration. <i>Methods in Molecular Biology</i> , 2020, 2145, 59-75.	0.4	1
11	Capsid Engineering Overcomes Barriers Toward Adeno-Associated Virus Vector-Mediated Transduction of Endothelial Cells. <i>Human Gene Therapy</i> , 2019, 30, 1284-1296.	1.4	23
12	Effective In Vivo Topical Delivery of siRNA and Gene Silencing in Intact Corneal Epithelium Using a Modified Cell-Penetrating Peptide. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 17, 891-906.	2.3	32
13	Evaluation of TGFBI corneal dystrophy and molecular diagnostic testing. <i>Eye</i> , 2019, 33, 874-881.	1.1	21
14	Personalised genome editing "The future for corneal dystrophies. <i>Progress in Retinal and Eye Research</i> , 2018, 65, 147-165.	7.3	31
15	Towards personalised allele-specific CRISPR gene editing to treat autosomal dominant disorders. <i>Scientific Reports</i> , 2017, 7, 16174.	1.6	66